KRYS
Krystal Biotech, Inc.
$312.37
▼ -8.43%
−$28.75
$312.37
▼ -8.43% · −$28.75 today
AI research · $312.37
KRYS, researched
Growth remains strong, but revenue execution is under scrutiny
refreshed Aug 3
price position
Where KRYS sits now
52-week range
Low$130.50
High$382.54
Today $312.37
RSI (14)
33.7Neutral
03070100
today's move
▼ -8.4%−$28.75
Revenue Miss Overshadows Krystal Biotech’s Earnings Beat
highKrystal Biotech’s second-quarter EPS beat expectations, but VYJUVEK revenue of $119.2 million came in below the $122.3 million forecast. The shortfall appears to have outweighed 24% year-over-year growth and strong margins, prompting investors to sell the shares sharply.
fundamentals
Business quality and valuation
Operating record
What the business has actually produced
Revenue
Capital structure
Cash versus debt
Cash & investments$823.4M
Total debt$9.1M
Net cash after debt$814.3M
Valuation
What the market charges
Forward P/E
Price against expected earnings
Needs attention · 115% above Sector avg
43.45x
Price / sales
Value assigned to each sales dollar
Rich · Above 8x annual sales
24.10x
Price / FCF
Price against free cash generation
Rich · Above 35x free cash flow
42.36x
EV / EBITDA
Operating value including debt
Rich · Above 22x EBITDA
48.84x
Quality
How efficiently it compounds
ROIC
Return earned on invested capital
Strong · At least 15% return on capital
41.4%
ROE
Profit generated from shareholder equity
Favorable · Ahead of most sector peers
19.9%
Debt / equity
Balance-sheet leverage
Favorable · Exceptional vs sector peers
0.01x
Current ratio
Short-term assets against liabilities
Strong · Comfortable short-term liquidity
9.46x
Selected financial data sourced from StockAnalysis and refreshed weekly. Figures may be delayed and are for research context, not investment advice.
peer comparison
How KRYS compares
| company | mkt cap | P/E | rev growth | score |
|---|---|---|---|---|
| $10.06B | 45.6 | +25.1% | 68 |
 | $10.69B | 18.4 | +23.5% | 78 |
 | $4.88B | 20.3 | +10.3% | 77 |
 | $31.49B | 32.9 | +15.5% | 77 |
 | $1.08T | 41.4 | +47.4% | 76 |
activity
What is moving KRYS
News
- 16h ago · Krystal Biotech, Inc. via Yahoo Finance
Krystal Biotech Shares Slide Despite Earnings Beat as Revenue Misses Forecasts
Bearish - 16h ago · Krystal Biotech, Inc. via Nasdaq
Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates
Mixed - 17h ago · Investing.com
Krystal Biotech stock falls 7% on revenue miss despite earnings beat - Investing.com
Bearish - 17h ago · Krystal Biotech, Inc. via Nasdaq
Krystal Biotech, Inc. Q2 Profit Climbs
Bullish
US stock research
About Krystal Biotech, Inc. (KRYS) stock
Krystal Biotech, Inc. tracked in the US core universe. KRYS was -8.4% in the latest available session at $312.37. Its reported market value was $10.06B with a trailing P/E of 45.6. Latest reported revenue was $417.30M, changing +25.1% year over year, with $225.03M in net income.
Market snapshot updated Aug 3, 2026, 7:59 PM UTC.
- Latest available price
- $312.37
- Day change
- -8.4%
- Market cap
- $10.06B
- P/E (TTM)
- 45.6
- Revenue growth
- +25.1%
- Industry
- Biotechnology